8 months in and amylin is still the thing I get wrong
Check-in as promised in the title: 8 months in and amylin is still the thing I get wrong.
8 months. Those are measured, not estimated, and not rounded up in my favour.
Kept a log purely because so few people are logging this one. It is one person and it is not data.
Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.
Sceptical readings welcome. The confident ones are the ones I distrust.
best — the order this archive was captured in
Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
amylin analogue, different receptor family, different story
Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.
amylin and GLP-1 are not redundant pathways
this is a less-travelled board and the evidence base shows it
long-acting amylin is the whole point of the molecule
nausea profile in the combination trials is the thing to read carefully
I would not extrapolate the tolerability profile from the monotherapy arm to the combination. The trials report them separately for a reason.
Not convinced. Amylin signalling is not a GLP-1 pathway and the mechanism you are proposing conflates them.
Careful — that is a dosing intuition carried over from another board and there is no basis for it here.
Careful — that is a dosing intuition carried over from another board and there is no basis for it here.
This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.
REDEFINE is the combination programme
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.
Not convinced.
hedda_aguirre is right that the evidence base here is thin. Conclusions should be held loosely.
- 1Combination and monotherapy arms must be read separately. Efficacy and…8 comments in this branch · started by u/noor_ivaturi
- 2Not convinced. Amylin signalling is not a GLP-1 pathway and the mechanism…6 comments in this branch · started by u/hedda_aguirre